Luye Files to Start China Trials of Class 1.1 Novel Analgesia Candidate

Luye Pharma of Yantai announced the CFDA accepted its IND filing for a China Class 1.1 novel analgesia candidate. LY03012 is an extended release oral treatment for chronic pain such as diabetic peripheral neuralgia, musculoskeletal pain and fibromyalgia. Although China is the first country to accept its IND , Luye intends to develop LY03012 in the US , Europe , Japan and other countries. The company expects to begin clinical trials soon. More details.... Stock Symbol: (HK: 2186) Share this with colleagues: // //